Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin inhalation - Aradigm

Next Previous
X
Search
Drug Profile

Ciprofloxacin inhalation - Aradigm

Alternative Names: Apulmiq; ARD-1100; ARD-3100; ARD-3150; CFI; Ciprofloxacin AERx formulation - Aradigm; Ciprofloxacin inhalation modified-release - Aradigm Corporation; Ciprofloxacin inhalation sustained-release - Aradigm; Ciprofloxacin liposomal sustained-release - Aradigm; DRCFI; Dual Release Ciprofloxacin for Inhalation; ILCH; Inhaled liposomal ciprofloxacin hydrochloride; Linhaliq; Lipoquin; Pulmaquin

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aradigm Corporation
  • Developer Aradigm Corporation; Oregon State University
  • Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis; Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acinetobacter infections; Anthrax; Bronchiectasis; Cystic fibrosis-associated respiratory tract infections; Nontuberculous mycobacterium infections; Pneumonic plague; Q fever; Tularaemia; Yersinia infections

Most Recent Events

  • 20 Apr 2022 Discontinued - Phase-II for Bronchiectasis (Non-cystic fibrosis-related) in United Kingdom, Canada, Germany, USA (Inhalation)
  • 20 Apr 2022 Discontinued - Phase-II for Cystic fibrosis-associated respiratory tract infections in New Zealand, Australia (Inhalation)
  • 20 Apr 2022 Discontinued - Phase-III for Bronchiectasis (Non-cystic fibrosis-related) in Peru, Taiwan, South Africa, Israel, South Korea, Georgia, Serbia and Montenegro, Canada, Australia, New Zealand (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top